Related Experiment Videos
Steering a course around the genetic iceberg.
1Institute of Medical and Social Care Research, University of Wales, Bangor. r.t.edwards@bangor.ac.uk
Journal of Public Health Medicine
|April 24, 2001
Summary
This study examines the implications of private genetic testing for breast and ovarian cancer predisposition, comparing the US and UK. It highlights the need to evaluate the cost-effectiveness and benefits of genetic services within differing healthcare systems.
Area of Science:
- Medical Ethics
- Health Economics
- Genetics
Background:
- Private companies offer direct-to-consumer genetic testing for cancer predisposition globally.
- Healthcare systems in the US and UK differ in their approach to genetic services.
- The UK National Health Service (NHS) faces increasing demand for genetic services.
Purpose of the Study:
- To explore concerns regarding private genetic testing in the US and UK.
- To evaluate the cost-effectiveness of expanding genetic services in the NHS.
- To determine how to best value the benefits of genetic information and counseling.
Main Methods:
- Comparative analysis of healthcare systems.
- Exploration of ethical and economic implications of genetic testing.
- Discussion of methods for valuing genetic information and counseling benefits.
Main Results:
- Calculating direct health benefits (e.g., life expectancy) from early diagnosis is feasible but applies to a small subset of women.
- Valuing the benefits of risk information and effective counseling presents significant challenges.
- The "genetic iceberg" phenomenon requires careful navigation by the NHS.
Conclusions:
- Efficient targeting of genetic services requires robust cost-effectiveness evaluations.
- Measuring and valuing the broader benefits of genetic information and counseling is crucial.
- Strategic planning is needed to integrate genetic advances into public healthcare systems like the NHS.